Aquestive Therapeutics, Inc. (AQST)
| Market Cap | 185.92M |
| Revenue (ttm) | 55.12M |
| Net Income (ttm) | -48.05M |
| Shares Out | 33.62M |
| EPS (ttm) | -1.51 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 26 |
| Last Price | $5.53 |
| Previous Close | $5.65 |
| Change ($) | -0.12 |
| Change (%) | -2.12% |
| Day's Open | 5.71 |
| Day's Range | 5.42 - 5.72 |
| Day's Volume | 639,088 |
| 52-Week Range | 1.54 - 9.09 |
WARREN, N.J., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that add...
WARREN, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that add...
Aquestive Therapeutics are back from the brink, with key advancements in Libervant resubmission and longevity in shareholder value creation. The company entered into a royalty agreement for KY...
WARREN, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that add...
Receives first milestone payment of $10 million, bringing total fourth quarter proceeds to $50 million Receives first milestone payment of $10 million, bringing total fourth quarter proceeds t...
WARREN, N.J., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that add...
Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q3 2020 Results - Earnings Call Transcript
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 2.00% and -3.05%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for...
WARREN, N.J., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that addr...
WARREN, N.J., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that add...
Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WARREN, N.J., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that add...
Recent disapproval from FDA regarding Libervant Buccal Film has seen investors react sourly over the last 2 weeks.
Aquestive Therapeutics Inc. (NASDAQ: AQST) has announced that it had received a Complete Response Letter (CRL) from the U.S.
WARREN, N.J., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that ...
Investors need to pay close attention to Aquestive Therapeutics (AQST) stock based on the movements in the options market lately.
WARREN, N.J., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that a...
Aquestive Therapeutics (AQST) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
WARREN, N.J., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that a...
Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q2 2020 Results - Earnings Call Transcript
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 83.72% and 137.27%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for th...
WARREN, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that ad...
WARREN, N.J., July 15, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that a...
WARREN, N.J., June 29, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that a...
WARREN, N.J., June 16, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that ad...
Aquestive Therapeutics (AQST) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
WARREN, N.J., May 21, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that add...
Is (AQST) Outperforming Other Medical Stocks This Year?
As of late, it has definitely been a great time to be an investor in Aquestive Therapeutics.
Aquestive Therapeutics (AQST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q1 2020 Results - Earnings Call Transcript
Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aquestive Therapeutics (AQST) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Top Ranked Momentum Stocks to Buy for April 14th
Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q4 2019 Results - Earnings Call Transcript
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -6.67% and 4.08%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for ...
WARREN, N.J., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated produ...
WARREN, N.J., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated produ...
As the biotechnology group is pushing near all-time highs, this past week played host to a huge number of biotech movers.
Aquestive Therapeutics Inc. (NASDAQ: AQST) shares lost nearly a third on Monday after the firm received an update from the U.S. Food and Drug Administration (FDA).
WARREN, N.J., Jan. 12, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated produ...
WARREN, N.J., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated produ...
Aquestive: Continues To Evolve Into A Promising Long-Term Investment
WARREN, N.J., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (Nasdaq:AQST) (“Aquestive”), a specialty pharmaceutical company focused on developing and commercializing differe...
WARREN, N.J., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (Nasdaq: AQST) (“Aquestive”), a specialty pharmaceutical company focused on developing and commercializing differ...
Top Ranked Momentum Stocks to Buy for December 9th
Aquestive Therapeutics Inc. (NASDAQ: AQST) shares jumped early on Monday after the firm announced the completion of its rolling submission of a New Drug Application (NDA) to the U.S. Food and ...
WARREN, N.J., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated prod...
Aquestive Therapeutics, Inc. (NASDAQ: AQST) shares jumped on Monday after the firm announced that its treatment of amyotrophic lateral sclerosis (ALS), Exservan, received early-action approval...
About AQST
Aquestive Therapeutics, a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemo... [Read more...]
| Industry Biotechnology | IPO Date Jul 25, 2018 |
| CEO Keith J. Kendall | Employees 232 |
| Stock Exchange NASDAQ | Ticker Symbol AQST |
Financial Performance
In 2019, AQST's revenue was $52.61 million, a decrease of -21.98% compared to the previous year's $67.43 million. Losses were -$66.25 million, 7.93% more than in 2018.
Analyst Forecasts
According to 6 analysts, the average rating for AQST stock is "Buy." The 12-month stock price forecast is 15.00, which is an increase of 171.25% from the latest price.